AVXL
Price:
$5.15
Market Cap:
$436.70M
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the trea...[Read more]
Industry
Biotechnology
IPO Date
2006-08-02
Stock Exchange
NASDAQ
Ticker
AVXL
According to Anavex Life Sciences Corp.’s latest financial reports and current stock price. The company's current PE Ratio is -10.10. This represents a change of -22.25% compared to the average of -12.99 of the last 4 quarters.
The mean historical PE Ratio of Anavex Life Sciences Corp. over the last ten years is -11.37. The current -10.10 PE Ratio has changed 8.79% with respect to the historical average. Over the past ten years (40 quarters), AVXL's PE Ratio was at its highest in in the September 2014 quarter at -0.24. The PE Ratio was at its lowest in in the June 2021 quarter at -39.63.
Average
-11.37
Median
-9.37
Minimum
-33.05
Maximum
-0.63
Discovering the peaks and valleys of Anavex Life Sciences Corp. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.26%
Maximum Annual PE Ratio = -0.63
Minimum Annual Increase = -88.68%
Minimum Annual PE Ratio = -33.05
Year | PE Ratio | Change |
---|---|---|
2023 | -11.00 | -33.48% |
2022 | -16.54 | -49.95% |
2021 | -33.05 | 228.05% |
2020 | -10.08 | 71.43% |
2019 | -5.88 | -10.96% |
2018 | -6.60 | -47.45% |
2017 | -12.56 | 45.07% |
2016 | -8.66 | 0.03% |
2015 | -8.66 | 1.26% |
2014 | -0.63 | -88.68% |
The current PE Ratio of Anavex Life Sciences Corp. (AVXL) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-20.20
5-year avg
-15.31
10-year avg
-11.37
Anavex Life Sciences Corp.’s PE Ratio is greater than Cassava Sciences, Inc. (-80.88), less than INmune Bio, Inc. (-3.01), less than BioVie Inc. (-3.07), less than Cognition Therapeutics, Inc. (-0.73), less than Annovis Bio, Inc. (-2.07), less than Iovance Biotherapeutics, Inc. (-6.48), greater than Axsome Therapeutics, Inc. (-14.37), less than Novavax, Inc. (-5.86), less than Exelixis, Inc. (20.78), less than TG Therapeutics, Inc. (33.32), greater than Viking Therapeutics, Inc. (-61.76), greater than Madrigal Pharmaceuticals, Inc. (-10.23), less than BioXcel Therapeutics, Inc. (-0.20), less than Reviva Pharmaceuticals Holdings, Inc. (-1.10), less than Eyenovia, Inc. (-0.70), less than TransCode Therapeutics, Inc. (-0.10), less than Kodiak Sciences Inc. (-0.61),
Company | PE Ratio | Market cap |
---|---|---|
-80.88 | $1.29B | |
-3.01 | $116.32M | |
-3.07 | $15.23M | |
-0.73 | $22.87M | |
-2.07 | $102.73M | |
-6.48 | $3.04B | |
-14.37 | $4.47B | |
-5.86 | $1.86B | |
20.78 | $7.17B | |
33.32 | $3.41B | |
-61.76 | $6.00B | |
-10.23 | $5.30B | |
-0.20 | $22.26M | |
-1.10 | $42.03M | |
-0.70 | $37.99M | |
-0.10 | $4.56M | |
-0.61 | $121.54M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Anavex Life Sciences Corp. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Anavex Life Sciences Corp. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Anavex Life Sciences Corp.'s PE Ratio?
How is the PE Ratio calculated for Anavex Life Sciences Corp. (AVXL)?
What is the highest PE Ratio for Anavex Life Sciences Corp. (AVXL)?
What is the 3-year average PE Ratio for Anavex Life Sciences Corp. (AVXL)?
What is the 5-year average PE Ratio for Anavex Life Sciences Corp. (AVXL)?
How does the current PE Ratio for Anavex Life Sciences Corp. (AVXL) compare to its historical average?